ESSENCE CS9 TIMI 73b is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~1320 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia.
MAIN RESULTS:
Targeting APOC3Â with Olezarsen in Moderate Hypertriglyceridemia
N Engl J Med. 2025 Oct 2;393(13):1279-1291.
MAIN RESULTS PRESENTATION
OTHER PRESENTATIONS
Essence-TIMI 73b CCTA Trial-Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis (Marston, ACC 2026)
Apolipoprotein C-III (APOC3) Inhibition in Patients With Versus Without Baseline Fibrate Use-A Prespecified Secondary Analysis of the ESSENCE-TIMI 73b Trial (Wang, ACC 2026)Â